Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shots:
- The companies collaborated to conduct a registrational P-III study of APG-2575 (Bcl-2 inhibitor) + AstraZeneca's Calquence (BTK) inhibitor) vs immunochemotherapy in treatment-naive patients with 1L CLL/SLL
- In the P-II study, lisaftoclax + acalabrutinib showed strong therapeutic potential with an ORR of 98% in patients with r/r CLL/SLL, ORR (100%) in treatment-naïve patients with an excellent safety profile The results were presented at ASH 2022
- Lisaftoclax is being studied in multiple clinical studies globally. Acalabrutinib was approved in 50+ countries/regions i.e., EU and Japan; was also approved for 2 indications incl. patients with MCL and adult patients with CLL/SLL
Ref: PR Newswire | Image: Ascentage
Related News:- Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
